2025 has been characterised by activities that strengthen the clinical program fordrug candidate ANXV. During the year, Annexin Pharmaceuticals has advanced its phase IIa-activities in ophthalmology, established an international medical expert council and represented the company at a number of international congresses where dialogues with potential licensing partners have been held. The company is now poised for business and the next stage of clinical development.
Read the article at biostock.se:
Annexin has laid the foundation for continued clinical development
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/